TOP > 外国特許検索 > NOVEL SUPRAMOLECULAR COMPOUND

NOVEL SUPRAMOLECULAR COMPOUND NEW

外国特許コード F180009564
整理番号 (S2017-0483-N0)
掲載日 2018年11月5日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP008991
国際公開番号 WO 2018164225
国際出願日 平成30年3月8日(2018.3.8)
国際公開日 平成30年9月13日(2018.9.13)
優先権データ
  • 特願2017-045352 (2017.3.9) JP
発明の名称 (英語) NOVEL SUPRAMOLECULAR COMPOUND NEW
発明の概要(英語) The purpose of the present invention is to provide a catenane containing β-cyclodextrin or a derivative thereof, and to provide a method for producing this catenane. The present invention provides a catenane that contains a compound represented by general formula (I) and a compound represented by general formula (II), wherein the compound represented by general formula (II) passes in a skewer-like configuration through the opening of the compound represented by general formula (I). The present invention also provides a method for producing this catenane.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, cyclic sugar malto cyclodextrin (CyD) and its derivatives, and lipid components of cancer cells by interacting with, various types of cancer for the type of anti-tumor activity have been reported.Grosse et al. for example, methyl β-CyD(M-β-CyD) derived from human breast cancer xenograft mouse administered intraperitoneally to a cell MCF7 and, is higher than the anti-tumor activity of doxorubicin was reported (Non-Patent Document 1).In addition, is Yokoo et al., hydroxypropyl (HP-β-CyD) β-CyD intraperitoneal administration, human chronic myelogenous leukemia-derived BaF3/BCR-ABL cell transplantation to a mouse, showing the effect of the anti-leukemia, the survival rate and to significantly increase the apparent (non-patent document 2).Further, the present inventors, (10-100 mg/kg) tumor M-β-CyD be administered, large intestine cancer cells derived from mouse to mouse allograft Colon-26, superior anti-tumor activity was determined.These reports, the anti-cancer agent CyDs additive formulation and suggest interesting finding and, in the development of new anti-cancer agent is a paradigm shift has been expected.However, the selectivity is low and thus the tumor CyDs these, together with the necessary high dose, concern about side effects.
Heretofore, the CyD as a component, such as rotaxane or a daisy chain of a variety of super-molecule has been synthesized, the synthesis of the catenane CyD said that it is difficult (Non-Patent Document 3), which is an example report of the catenane CyD very little.This is, in a state of penetrating in the molecule, binding both ends of the molecular axis (cyclization reaction) can be considered to be because it has a (non-patent document 4).Catenane CyD is reported up to now, the number of 1 or 2 and through the CyD, the number of 3 or more from the CyD configured to report the synthesis of the catenane, only the non-patent document 5.In non-patent document 5, the end cap and the anthracene molecule is irradiated with light of the polyrotaxane α-CyD, dimerization reaction of anthracene by cyclization of the polyrotaxane, attempting preparation.However, the physical properties of the polyrotaxane obtained in this way and almost the same, and from the other, isolated difficult only.Therefore, in non-patent document 5, only the formation of the inferred , is isolated and does not reach to the measurement of the properties, virtually CyD report is not successfully synthesized.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • Hidetoshi Arima
  • Keiichi Motoyama
  • Higashi Ori
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close